Bellerophon therapeutics announces license agreement for the commercialization of inopulse® in greater china with baylor biosciences

Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in greater china bellerophon to receive a license payment of $6 million, as well as royalties on net sales in greater china
BLPH Ratings Summary
BLPH Quant Ranking